drugset / Trial / NCT01931189

Pharmacokinetics Study of NI-071

NCT01931189

Phase 1 Completed 96 enrolled Nichi-Iko Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess equivalence of pharmacokinetics between NI-071 and infliximab(the comparator) in Japanese healthy volunteers

Timeline

Start
2013-08
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Infliximab Monoclonal antibody
Subject NI-071 Unknown

Indications

No indication recorded.